Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

oint; the ability to treat osteoporosis with an orally delivered therapeutic; the continued advancement of Unigene's oral PTH program; and Unigene's ability to build a robust portfolio of proprietary partnerships in peptide-based therapeutics based on its Peptelligence™ platform. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies and our ability to enter into favorable new agreements with such companies, our ability to cut expenses and maintain efficiencies, our ability to enter into new financing arrangements,  the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on F
'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Radial Strength, FlexibilityHOUSTON, March 18 IDEV Technologies ... and marketing of minimally invasive technologies, announced today ... has approved an investigational device exemption (IDE) for ... a novel stent platform designed for the treatment ...
... March 18 ULURU Inc. (NYSE Alternext: ULU) ... diabetic foot ulcers, and data on the use of ... presented at the annual DFCon Global Meeting in Los ... presented on posters that will be on display during ...
Cached Medicine Technology:U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... The following is a,statement by Steve Case, Co-Founder, AOL and ... Kennedy,s brain cancer diagnosis:, "I was deeply saddened to ... ago I had the opportunity to testify at a hearing ... efforts to fight,cancer, and was able to share some of ...
... Aflac Announces Full-Season Multi-Year Sponsorship, COLUMBUS, Ga., ... ),today announced its signing of a full-season multi-year ... and the No. 99 Ford Fusion.,Additionally, Aflac continues ... Roush Fenway Racing and Carl Edwards., (Photo: ...
... Eye(TM) Retroscope(TM) Improved Polyp Detection by Thirteen Percent, ... Digestive Disease Week,conference in San Diego (DDW 2008), ... from a multi-institutional,study which evaluated the efficacy of ... the ability of physicians to visualize,abnormalities in the ...
... American Thoracic Societys 2008 International Conference in Toronto on Wednesday, ... in young adults. One links low levels of a protein ... risk in young women. A second finds that high levels ... function. , The data from both studies comes from ...
... Crdentia Corp. (OTC Bulletin,Board: CRDT), a leading healthcare staffing ... 31, 2008., Revenue in the quarter was $10,579,387, ... $9,806,540 and an increase of 31% over revenue of,$8,097,329 ... to,$2,310,854 in the first quarter of 2008, compared to ...
... TORONTOA large group of soldiers returning from Iraq ... the small airways of the lung, according to ... their findings at the American Thoracic Societys 2008 ... A total of 56 soldiers from Fort Campbell, ...
Cached Medicine News:Health News:Aflac to be Primary Sponsor of Carl Edwards and the No. 99 Ford Fusion 2Health News:Aflac to be Primary Sponsor of Carl Edwards and the No. 99 Ford Fusion 3Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 2Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 3Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 4Health News:Study presented at DDW 2008 Confirms that New Device Significantly Improves Detection of Polyps in the Colon 5Health News:Studies provide insights into lung disease and lung function in young adults 2Health News:Studies provide insights into lung disease and lung function in young adults 3Health News:Crdentia Announces 2008 First Quarter Results 2Health News:Crdentia Announces 2008 First Quarter Results 3Health News:Crdentia Announces 2008 First Quarter Results 4Health News:Crdentia Announces 2008 First Quarter Results 5Health News:Crdentia Announces 2008 First Quarter Results 6Health News:Crdentia Announces 2008 First Quarter Results 7Health News:Iraq war service: A risk factor for bronchiolitis? 2
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Fulgurating Electrode, 2 F...
ACMI S-Series Cystourethroscope Systems: Precision instruments designed for superior optical recognition, accurate control, and exceptional durability during steam autoclave sterilization....
Medicine Products: